MajorClass III antiarrhythmic×Direct oral anticoagulants (factor Xa inhibitors)
Updated · Methodology
Mechanism
Dronedarone strongly inhibits the transporter P-glycoprotein (P-gp) and moderately inhibits the enzyme CYP3A4 (dronedarone summary of product characteristics, SmPC, European Medicines Agency, EMA). Edoxaban is a P-gp substrate, and CYP3A4/5 accounts for less than 10% of its metabolism (edoxaban SmPC, EMA). Dronedarone 400 mg twice daily for 7 days increased the edoxaban area under the concentration–time curve (AUC) by 85% and its peak concentration by 46% (edoxaban SmPC, EMA). Dronedarone itself raises serum creatinine by 10 µmol/L on average, usually early in treatment, with a plateau after 7 days (dronedarone SmPC, EMA). The edoxaban dose depends on creatinine clearance (edoxaban SmPC, EMA).
Symptoms
The main risk is bleeding. It can occur at any site and can be severe or even fatal (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia. Gastrointestinal bleeding, vaginal bleeding and bleeding into the skin are common. Intracranial bleeding is uncommon, and menstrual bleeding may become heavier or last longer (edoxaban SmPC, EMA). Bleeding can present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause. An unexplained fall in haemoglobin or blood pressure points to hidden bleeding (edoxaban SmPC, EMA).
Management
With dronedarone, the recommended edoxaban dose is 30 mg once daily instead of the usual 60 mg (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). The dronedarone SmPC also says to reduce the edoxaban dose according to the edoxaban product information (dronedarone SmPC, EMA). The European Heart Rhythm Association table gives the same 30 mg dose (EHRA 2021). Several reasons for reduction do not lower the dose further. With creatinine clearance of 15–50 mL/min or body weight of 60 kg or less as well, it stays at 30 mg (edoxaban SmPC, EMA). Dronedarone is contraindicated when creatinine clearance is below 30 mL/min (dronedarone SmPC, EMA). Measure creatinine before starting dronedarone and after 7 days. If it has risen, measure it again after another 7 days. If there is no further rise, use this value as the new baseline, and then check kidney function regularly (dronedarone SmPC, EMA). During dronedarone treatment, monitor co-administered anticoagulants (dronedarone SmPC, EMA). Promptly evaluate any signs of blood loss (edoxaban label, US Food and Drug Administration, FDA), and stop edoxaban if severe bleeding occurs (edoxaban SmPC, EMA). There is no specific antidote. For life-threatening bleeding that cannot be controlled, the SmPC describes a 4-factor prothrombin complex concentrate at 50 IU/kg. It reversed the effects of edoxaban 30 minutes after the end of the infusion (edoxaban SmPC, EMA). In the USA, the edoxaban dose for atrial fibrillation is not reduced because of P-glycoprotein (P-gp) inhibitors. In the ENGAGE AF-TIMI 48 trial, patients taking these inhibitors who received the reduced dose had lower edoxaban levels than patients given the full dose (edoxaban label, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EHRA: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (2021)– Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–1676, Tables 5–8 and Figure 6
- EMA: Ficha técnica: Dronedarona, Multaq 400 mg (EU/1/09/591) (2024)– EMA SmPC vía AEMPS CIMA, nº registro 09591003 (Multaq 400 mg comprimidos recubiertos con película, EU/1/09/591), revisión del texto 07/2024, secciones 4.3, 4.4 y 4.5
- FDA: SAVAYSA (edoxaban) tablets, prescribing information (2023)– FDA, SAVAYSA (edoxaban tosylate) prescribing information, Daiichi Sankyo, NDA 206316, revised 10/2023 (DailyMed)
- EMA: Ficha técnica: Edoxabán, Lixiana 60 mg (EU/1/15/993), secciones 4.4 y 4.5 (2025)– EMA, ficha técnica de Lixiana 60 mg comprimidos recubiertos con película (Daiichi Sankyo Europe), EU/1/15/993, texto en CIMA nº registro 115993018, información del producto de la EMA actualizada 27/08/2025, secciones 4.2, 4.3, 4.4, 4.5, 4.8, 4.9 y 5.2